STRO — SUTRO BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1382101 ·
Last close
$8.92
Market Cap
$148.08M
52W High
$43.85
52W Low
$7.15
ADV30
336,899
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 9,098,000 | — | -21,940,000 | -31,489,000 | 176,648,000 | 46,851,000 | 309,184,000 |
| Jun 2026 | 9,839,000 | — | -29,687,000 | -38,533,000 | 194,462,000 | 54,335,000 | 297,779,000 |
| Mar 2026 | 14,523,000 | — | -29,614,000 | -38,484,000 | 241,988,000 | 73,682,000 | 308,875,000 |
| Dec 2025 | 11,647,000 | — | -33,657,000 | -46,762,000 | 173,830,000 | 58,130,000 | 306,282,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-145,173,000
Investing CF
$32,788,000
Financing CF
$102,695,000
CapEx
$-532,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.37
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,054,972,000
Inventory
—
Receivables
$5,797,000
ST Investments
$110,011,000
EBIT TTM
$-139,151,000
Pretax Income TTM
$-180,732,000
Interest Exp TTM
$41,581,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$45,107,000
EBITDA
$-109,490,000
Free Cash Flow
$-105,745,376
Enterprise Value
$30,548,856
Total Cash
$142,176,992
Total Debt
$9,700,000
Shares Out
16,601,411
Trailing EPS
$-12.42
Book Value
$-7.99
ROE
—
ROA
-37.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 102,484,000 | -104,952,000 | -191,086,000 | 173,830,000 | 306,282,000 | -132,452,000 | -177,231,000 |
| Dec 2024 | 62,043,000 | -238,453,000 | -227,461,000 | 387,207,000 | 342,606,000 | 44,601,000 | -191,540,000 |
| Dec 2023 | 153,731,000 | -89,278,000 | -106,793,000 | 470,736,000 | 321,087,000 | 149,649,000 | -111,616,000 |
| Dec 2022 | 67,772,000 | -128,943,000 | -119,204,000 | 406,944,000 | 189,896,000 | 217,048,000 | 3,549,000 |
TTM Snapshot
Revenues TTM
$45,702,000
NetIncome TTM
$-180,636,000
OpCashFlow TTM
—
Assets (Latest)
$194,462,000
Forward EPS
$-6.07
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $8.50 · call volume: 42 · put volume: 4Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPHA | Innate Pharma SA | $148.56M | $1.33 | — |
| IVVD | Invivyd, Inc. | $151.09M | $0.51 | — |
| HUMA | Humacyte, Inc. | $139.18M | $0.50 | — |
| TARA | Protara Therapeutics, Inc. | $137.10M | $2.32 | — |
| IPHYF | Innate Pharma SA | $168.56M | $1.51 | — |
News headlines (Yahoo Finance, 1h cache)
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-12 21:30 · Yahoo
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
2026-11-04 13:35 · Yahoo
Sutro Biopharma to Participate in Upcoming Investor Conferences
2026-11-04 13:00 · Yahoo
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
2026-11-03 13:35 · Yahoo
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
2026-10-21 12:00 · Yahoo
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
2026-10-12 12:00 · Yahoo
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
2026-09-29 12:00 · Yahoo
STRO Stock Plummets 15% — What Drove The Selloff?
2026-08-12 20:07 · Yahoo
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-12 11:00 · Yahoo
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
2026-05-17 13:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.